Primary Leptomeningeal Oligodendroglioma, IDH-Mutant, 1p/19q-Codeleted

被引:0
|
作者
Ballester, Leomar Y. [1 ,2 ]
Dunbar, Erin [3 ]
Guha-Thakurta, Nandita [4 ]
Henson, John W. [3 ]
Chandler, Howard [3 ]
Watkins, Jeremiah [3 ]
Fuller, Gregory N. [5 ]
机构
[1] Dept Pathol & Lab Med, Houston, TX 77225 USA
[2] Univ Texas Hlth Sci Ctr Houston, Neurosurg, Houston, TX 77030 USA
[3] Piedmont Canc, Piedmont Brain Tumor Ctr, Atlanta, GA USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Diagnost Radiol, Houston, TX 77030 USA
[5] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA
来源
FRONTIERS IN NEUROLOGY | 2018年 / 9卷
关键词
leptomeningeal oligodendroglioma; IDH1; 1p/19q-codeletion; diffuse glioma; CIC; ATRX; FUBP1; 1P DELETION; GRADE II; TEMOZOLOMIDE; NEOPLASMS; GLIOMAS;
D O I
10.3389/fneur.2018.00700
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
We present a case of a 43-year-old woman with a history of headaches and blurry vision. Ophthalmologic examination identified papilledema. MR imaging demonstrated a right parietal region mass with patchy areas of contrast enhancement and focal calcifications. Intraoperative examination and exploration revealed an extra-axial mass with no apparent parenchymal involvement. Microscopic examination revealed solid sheets of tumor cells with clear cell cytologic features and no discernable intra-parenchymal tumor component. Molecular studies demonstrated the presence of IDH1 IDH1 c.395G>A p.R132H and C/C c.601C>T p.R281W mutations and 1p/19q codeletion. The radiographic features, gross appearance, and microscopic and molecular characteristics of the mass support the diagnosis of primary leptomeningeal oligodendroglioma, IDH-mutant, 1p/19-codeleted. This case represents one of a very few reported instances of molecularly-defined solitary, primary, intracranial oligodendroglioma, without definitive involvement of the brain parenchyma.
引用
收藏
页数:4
相关论文
共 50 条
  • [21] Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma
    Kacimi, Salah Eddine O.
    Dehais, Caroline
    Feuvret, Loic
    Chinot, Olivier
    Carpentier, Catherine
    Bronnimann, Charlotte
    Vauleon, Elodie
    Djelad, Apolline
    Cohen-Jonathan Moyal, Elizabeth
    Langlois, Olivier
    Campone, Mario
    Ducloie, Mathilde
    Noel, Georges
    Cuzzubbo, Stefania
    Taillandier, Luc
    Ramirez, Carole
    Younan, Nadia
    Menei, Philippe
    Dhermain, Frederic
    Desenclos, Christine
    Ghiringhelli, Francois
    Bourg, Veronique
    Ricard, Damien
    Faillot, Thierry
    Appay, Romain
    Tabouret, Emeline
    Nichelli, Lucia
    Mathon, Bertrand
    Thomas, Alice
    Tran, Suzanne
    Bielle, Franck
    Alentorn, Agusti
    Iorgulescu, J. Bryan
    Boelle, Pierre-Yves
    Labreche, Karim
    Hoang-Xuan, Khe
    Sanson, Marc
    Idbaih, Ahmed
    Figarella-Branger, Dominique
    Ducray, Francois
    Touat, Mehdi
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (03)
  • [22] The cortical high-flow sign of oligodendroglioma, IDH-mutant and 1p/19q-codeleted: comparison between arterial spin labeling and dynamic susceptibility contrast methods
    Yamashita, Koji
    Togao, Osamu
    Kikuchi, Kazufumi
    Kuga, Daisuke
    Sangatsuda, Yuhei
    Fujioka, Yutaka
    Yoshimoto, Koji
    Ishigami, Kousei
    NEURORADIOLOGY, 2024, 66 (02) : 187 - 192
  • [23] Synchronous gemistocytic astrocytoma IDH-mutant and oligodendroglioma IDH-mutant and 1p19q-codeleted in a patient with CCDC26 polymorphism
    Vaubel, Rachael
    Kollmeyer, Thomas
    Caron, Alissa
    Fritcher, Emily Barr
    Voss, Jesse
    Liang, Haohai
    Jenkins, Robert
    Kipp, Benjamin
    Giannini, Caterina
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2017, 76 (06): : 512 - 512
  • [24] High aneuploidy is a predictor of aggressive behavior in oligodendroglioma, IDH-mutant, 1p19q codeleted
    Belakhoua, S.
    Serrano, J.
    Garcia, M.
    Schroff, C.
    Tran, I.
    Galbraith, K.
    Snuderl, M.
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2023, 82 (06): : 526 - 527
  • [25] Clinical Outcomes of Reirradiation in IDH-Mutant Astrocytomas and 1p/19q Codeleted Oligodendrogliomas
    Rudra, S.
    Robinson, C. G.
    Tsien, C.
    Campian, J. L.
    Ansstas, G.
    Chicoine, M.
    Rich, K.
    Kim, A. H.
    Huang, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : E342 - E342
  • [26] Treating oligodendroglioma - An analysis of a homogeneous 1p/19q-codeleted and isocitrate dehydrogenase-mutant patient cohort
    Allwohn, Luisa
    Wolfgang, Josy
    Onken, Julia
    Wasilewski, David
    Roohani, Siyer
    Zips, Daniel
    Ehret, Felix
    Kaul, David
    CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 2023, 41
  • [27] Oligodendroglioma, IDH-mutant and 1p/19q-codeleted-prognostic factors, standard of care and chemotherapy, and future perspectives with neoadjuvant strategy
    Hikaru Sasaki
    Yohei Kitamura
    Masahiro Toda
    Yuichi Hirose
    Kazunari Yoshida
    Brain Tumor Pathology, 2024, 41 : 43 - 49
  • [28] Oligodendroglioma, IDH-mutant and 1p/19q-codeleted-prognostic factors, standard of care and chemotherapy, and future perspectives with neoadjuvant strategy
    Sasaki, Hikaru
    Kitamura, Yohei
    Toda, Masahiro
    Hirose, Yuichi
    Yoshida, Kazunari
    BRAIN TUMOR PATHOLOGY, 2024, 41 (02) : 43 - 49
  • [29] A review of adult-type diffuse gliomas in the WHO CNS5 classification with special reference to Astrocytoma, IDH-mutant and Oligodendroglioma, IDH-mutant and 1p/19q codeleted
    Santosh, Vani
    Rao, Shilpa
    INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY, 2022, 65 (05) : 14 - 23
  • [30] Oligodendrogliomas, IDH-mutant and 1p/19q-codeleted, arising during teenage years often lack TERT promoter mutation that is typical of their adult counterparts
    Julieann Lee
    Angelica R. Putnam
    Samuel H. Chesier
    Anuradha Banerjee
    Corey Raffel
    Jessica Van Ziffle
    Courtney Onodera
    James P. Grenert
    Boris C. Bastian
    Arie Perry
    David A. Solomon
    Acta Neuropathologica Communications, 6